Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Defense-to-Offense: PhRMA Readies to Protect Government Markets

This article was originally published in RPM Report

Executive Summary

White House budget targeting biopharma with new cuts hits just as the Pharmaceutical Research & Manufacturers of America’s annual meeting gets under way.

You may also be interested in...

FDA Adapts Drug Development Tool Procedures to Adopt Alzheimer’s Simulation Tool

FDA recently featured an Alzheimer’s Disease clinical trial simulation tool as another positive, but low-visibility, step toward improving the drug development pathway for the disease. The process for accepting the tool may be as important as the tool itself.

PhRMA 2014: IP, Research, and Reputation

NIH research support, intellectual property protections, and restoring the drug industry’s image moved up on the list of podium priorities at the PhRMA annual meeting in Washington, DC.

For PhRMA in 2011, Government Relations Relies on Governor Relations

Jobs and governors go together like bread and butter. PhRMA is using the employment strength and new-economy mystique of biopharmaceuticals to try to line up strong advocates from the state houses in the upcoming fights over where to cut in health care spending.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts